First phase 3 study of MDMA-assisted therapy for severe PTSD

The first phase three trial of psychedelic assisted therapy has shown that MDMA could be an effective new treatment for severe PTSD. There were 90 participants in this study and those who received MDMA alongside therapy reported a significant reduction in symptom severity compare with participants who received therapy and a placebo. Two months after treatment 67% of participants in the MDMA assisted group had reached remission, more than double the number of participants in the placebo assisted group (32%).

There were no serious side effects from the MDMA treatment however some mild side effects did include nausea and appetite loss for some participants.

To read the paper visit https://www.nature.com/article...